Shankar Gopi 4

What Happened

• Shankar Gopi, Chief Development Officer of Larimar Therapeutics (LRMR), received two awards on January 26, 2026 totaling 179,459 shares: 25,637 restricted stock units (RSUs) and 153,822 derivative awards. Both were reported as acquisitions at a $0.00 price (no cash paid). These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-01-26; Form 4 filed: 2026-01-27 (timely filing).
• Awards: 25,637 RSUs (each RSU = contingent right to one share) and 153,822 derivative shares; total = 179,459 shares; reported acquisition code: A.
• Price: $0.00 per share (grant/award).
• Vesting/terms: Footnote indicates RSUs settle into common stock upon settlement. A separate footnote states the option/award vests 25% on Jan 26, 2027, then the remaining 75% vests in equal monthly installments over the next 36 months, subject to continued service.
• Shares owned following the transaction: not disclosed in the provided filing excerpt.

Context

• These awards are compensation grants (non-cash) and typically reflect retention or incentive arrangements; they are not immediate sales or purchases in the open market.
• The larger 153,822-item is a derivative award with a multi-year vesting schedule—no immediate liquidity is indicated.
• For retail investors, grants are informative about company compensation practices but do not directly signal buying/selling pressure.